A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma

Mayo Clinic

Status: Completed

Conditions: Multiple Myeloma

Treatments: Other: Non-Interventional Study

Study type: Observational

Funder types: Other

Identifiers

NCT06151717

NCI-2023-09520 (Registry Identifier)

MC230811 (Other Identifier)

23-006335 (Other Identifier)

PRAGMMATIC (Other Identifier)

Details and patient eligibility

About

This study evaluates the outcomes of patients undergoing initial therapy for multiple myeloma.

Full description

PRIMARY OBJECTIVE:

I. Compare the overall survival between bortezomib, lenalidomide and dexamethasone (VRd), daratumumab, lenalidomide and dexamethasone (DRd) and daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) used as initial therapy for patients with newly diagnosed MM.

OUTLINE: This is an observational study.

Patients have their medical records reviewed on study.

Enrollment: 50 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Previously untreated active multiple myeloma starting a new treatment for the disease with one of the three established treatment regimens: VRd (bortezomib, lenalidomide, dexamethasone), DRd (daratumumab lenalidomide dexamethasone), or DVRd (daratumumab, bortezomib, lenalidomide, and dexamethasone)
• No prior treatment for myeloma
• Not receiving concurrent treatment for another active malignancy
• No more than 3 months from start of treatment

Exclusion criteria

• Does not meet all inclusion criteria

Trial design

50 participants in 1 patient group

Observational

Description:

Patients have their medical records reviewed on study.

Treatment:

Other: Non-Interventional Study